Table 1:
Descriptive statistics of breast cancer management for the treatment modalities of surgery, chemotherapy (CT) and endocrine therapy (ET) in women diagnosed with non-metastatic breast cancer with known TNM stage in the ABC-DO cohort
| Namibia black | Namibia non-black | Nigeria | SA black | SA mixed-race | Uganda | Zambia | Total | ||
|---|---|---|---|---|---|---|---|---|---|
| No. study sample with non-metastatic breast cancer | 309 | 91 | 292 | 544 | 34 | 296 | 150 | 1716 | |
| Subset populating the denominator | N (column % among women who received the respective treatment) | ||||||||
| Breast cancer surgery performed | Whole study sample | 221/309 (71) | 82/91 (90) | 156/292 (53) | 415/544 (76) | 28/34 (82) | 182/296 (61) | 79/150 (53) | 1163/1716 (68) |
| Mastectomy performed | Received surgery | 205/221 (93) | 66/82 (80) | 80/156 (51) | 297/415 (71) | 18/28 (64) | 167/182 (92) | 76/79 (96) | 909/1163 (78) |
| Received consecutive radiotherapy | Received mastectomy | 160/205 (78) | 43/66 (65) | 7/80 (9) | 127/297 (43) | 12/18 (67) | 45/167 (27) | 32/76 (42) | 426/909 (47) |
| Breast conserving surgery | Received surgery | 16/221 (7) | 16/82 (20) | 76/156 (49) | 119/415 (29) | 10/28 (36) | 15/182 (8) | 3/79 (4) | 255/1163 (22) |
| Received consecutive radiotherapy | Received breast conserving surgery | 13/16 (81) | 15/16 (94) | 2/76 (3) | 67/119 (56) | 6/10 (60) | 4/15 (27) | 0/3 (0) | 107/255 (42) |
| Nodes dissected | Received surgery | ||||||||
| Not done | “ | 11/221 (5) | 0/82 (0) | 4/156 (3) | 6/415 (1) | 0/28 (0) | 23/182 (13) | 1/79 (1) | 45/1163 (4) |
| Sentinel or sampling | “ | 26/221 (12) | 15/82 (18) | 3/156 (2) | 0/415 (0) | 0/28 (0) | 0/182 (0) | 0/79 (0) | 44/1163 (4) |
| Complete axillary node dissection | “ | 40/221 (18) | 11/82 (13) | 6/156 (4) | 361/415 (87) | 26/28 (93) | 8/182 (4) | 4/79 (5) | 456/1163 (39) |
| unknown | “ | 144/221 (65) | 56/82 (68) | 143/156 (92) | 48/415 (12) | 2/28 (7) | 151/182 (83) | 74/79 (94) | 618/1163 (53) |
| Additional systemic therapyA | Received surgery | ||||||||
| Neoadjuvant | “ | 132/221 (60) | 45/82 (55) | 69/156 (44) | 157/415 (38) | 9/28 (32) | 23/182 (13) | 40/79 (51) | 475/1163 (41) |
| Adjuvant | “ | 143/221 (65) | 61/82 (74) | 76/156 (49) | 332/415 (80) | 25/28 (89) | 167/182 (92) | 47/79 (59) | 851/1163 (73) |
| No systemic therapy | “ | 6/221 (3) | 2/82 (2) | 35/156 (22) | 19/415 (5) | 1/28 (4) | 12/182 (7) | 9/79 (11) | 84/1163 (7) |
| Chemotherapy initiated | Whole study sample | 245/309 (79) | 65/91 (71) | 143/292 (49) | 415/544 (76) | 27/34 (79) | 228/296 (77) | 109/150 (73) | 1232/1716 (72) |
| Timing of chemotherapy | Initiated chemotherapy | ||||||||
| NeoadjuvantB | “ | 187/245 (76) | 44/65 (68) | 89/143 (62) | 226/415 (54) | 13/27 (48) | 75/228 (33) | 80/109 (73) | 714/1232 (58) |
| Adjuvant | “ | 58/245 (24) | 21/65 (32) | 54/143 (38) | 189/415 (46) | 14/27 (52) | 153/228 (67) | 29/109 (27) | 518/1232 (42) |
| Regimen C | Initiated chemotherapy | ||||||||
| AC/CMF | “ | 36/245 (15) | 16/65 (25) | 22/143 (15) | 75/415 (18) | 7/27 (26) | 8/228 (4) | 8/109 (7) | 172/1232 (14) |
| FAC | “ | 63/245 (26) | 6/65 (9) | 56/143 (39) | 31/415 (7) | 1/27 (4) | 44/228 (19) | 37/109 (34) | 238/1232 (19) |
| (F)AC-T | “ | 131/245 (543) | 34/65 (52) | 6/143 (4) | 253/415 (61) | 16/27 (59) | 6/228 (3) | 40/109 (37) | 486/1232 (39) |
| non-standard | “ | 6/245 (2) | 5/65 (8) | 7/143 (5) | 28/415 (7) | 1/27 (4) | 0/228 (0) | 2/109 (2) | 49/1232 (4) |
| unknown | “ | 9/245 (4) | 4/65 (6) | 52/143 (36) | 28/415 (7) | 2/27 (7) | 170/228 (75) | 22/109 (20) | 287/1232 (23) |
| Trastuzumab received | Whole study sample | 36/309 (12) | 9/91 (10) | 1/292 (0.3) | 1/544 (0.2) | 0/34 (0) | 0/296 (0) | 0/150 (0) | 47/1716 (3) |
| ET initiated | “ | 233/309 (75) | 70/91 (77) | 109/292 (37) | 309/544 (57) | 26/34 (77) | 161/296 (54) | 65/150 (43) | 973/1716 (57) |
| Timing | Initiated ET | ||||||||
| Neoadjuvant D | “ | 97/233 (42) | 15/70 (21) | 66/109 (61) | 42/309 (14) | 3/26 (12) | 56/161 (35) | 33/65 (51) | 312/973 (32) |
| Adjuvant | “ | 131/233 (56) | 55/70 (79) | 43/109 (39) | 267/309 (86) | 23/26 (88) | 95/161 (59) | 31/65 (48) | 645/973 (66) |
| Unknown | “ | 5/233 (2) | 0/70 (0) | 0/109 (0) | 0/309 (0) | 0/26 (0) | 10/161 (6) | 1/65 (2) | 16/973 (2) |
| Drug | Initiated ET | ||||||||
| Tamoxifen | “ | 196/233 (84) | 46/70 (66) | 107/109 (98) | 304/309 (98) | 25/26 (96) | 145/161 (90) | 60/65 (92) | 883/973 (91) |
| Aromatase inhibitor | “ | 5/233 (2) | 17/70 (24) | 0/109 (0) | 5/309 (2) | 1/26 (4) | 3/161 (2) | 0/65 (0) | 31/973 (3) |
| Tamoxifen -> Aromatase inhibitors | “ | 27/233 (12) | 7/70 (10) | 1/109 (1) | 0/309 (0) | 0/26 (0) | 11/161 (7) | 4/65 (6) | 50/973 (5) |
| Unable to determine | “ | 5/233 (2) | 0/70 (0) | 1/109 (1) | 0/309 (0) | 0/26 (0) | 2/161 (1) | 1/65 (2) | 9/973 (1) |
| Ovarian ablation | Whole study sample | 12/309 (4) | 2/91 (2) | 0/292 (0) | 0/544 (0) | 0/34 (0) | 0/296 (0) | 0/150 (0) | 14/1716 (1) |
A
Column percentage >100% due to 247 women receiving neoadjuvant and adjuvant systemic therapy;
B
Including 287 women not receiving surgery after initiated chemotherapy;
C
Information only available in subsample with medical CT records (N=975). Chemotherapy drugs contained in regimens: Cyclophosphamide (C), Doxorubicin (Adriamycin; A), Fluorouracil (F), Methotrexate (M) and Taxane (T). Amongst 50 patients with non-standard regimen: 41 patients received Taxane only, 2 Xeloda only, 5 Carboplatin and 1 Cyclophosphamide and Carboplatin;
D
Including 84 women not receiving surgery after initiated endocrine therapy